TrialThe Lancet. Oncology2022

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.

David Cella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.